Darunavir Ethanolate & Ritonavir Tablets 400mg/50mg Manufacturer Supplier in India

Taj Pharma is one of the most trusted and reputed Darunavir Ethanolate & Ritonavir Tablets 400mg/50mg manufacturers in India, recognized for its commitment to quality, global regulatory compliance, and large-scale pharmaceutical export capabilities. As a pioneer in HIV antiretroviral therapy manufacturing, Taj Pharma has established itself as a global exporter and supplier of Darunavir & Ritonavir Tablets 400mg/50mg, catering to hospitals, NGOs, and government health programs across Africa, the Middle East, Latin America (LATAM), and Asia.


What Are Darunavir Ethanolate & Ritonavir Tablets 400mg/50mg?

Darunavir Ethanolate & Ritonavir Tablets 400mg/50mg are a combination of two potent antiretroviral drugs used for the treatment of HIV-1 infection. This fixed-dose combination includes Darunavir (400mg) and Ritonavir (50mg)—both protease inhibitors that work synergistically to suppress HIV replication.

  • Darunavir Ethanolate: A protease inhibitor that prevents viral replication by blocking the protease enzyme needed by the virus to mature and multiply.
  • Ritonavir: Enhances the plasma concentration of Darunavir by inhibiting its metabolism, leading to improved efficacy and sustained viral suppression.

This combination is prescribed as part of an antiretroviral therapy (ART) regimen, often alongside other HIV medications, to reduce viral load and improve immune function.


A Trusted Name in HIV Antiretroviral Manufacturing

Taj Pharma India stands as a top manufacturer and exporter of Darunavir Ethanolate & Ritonavir Tablets 400mg/50mg from its world-class production facility in Vapi, Gujarat. Known for adhering to stringent international quality standards, Taj Pharma manufactures its formulations in WHO-GMP, FDA, and ISO-certified facilities, ensuring compliance with global pharmaceutical norms.

Key Strengths of Taj Pharma India

  • WHO-GMP Certified Manufacturing Units
  • Compliant with International Pharmacopeia Standards (USP, BP, IP)
  • Validated cGMP Manufacturing Practices
  • Regulatory Documentation (CTD/eCTD Dossier Support)
  • Strong R&D and Quality Assurance Infrastructure

By leveraging advanced manufacturing technologies and a robust distribution network, Taj Pharma ensures timely supply of high-quality HIV drugs across Africa, the Middle East, and Latin America.


Therapeutic Use: HIV Infection Treatment

Darunavir Ethanolate & Ritonavir Tablets 400mg/50mg are primarily indicated for the treatment of Human Immunodeficiency Virus Type 1 (HIV-1) infection. This fixed-dose combination inhibits the viral replication process, helping to:

  • Reduce viral load in the bloodstream
  • Increase CD4 cell counts
  • Improve immune system function
  • Delay progression to AIDS

This therapy is especially effective when used in combination with other antiretroviral drugs as part of HAART (Highly Active Antiretroviral Therapy).


Mechanism of Action

Both Darunavir and Ritonavir belong to the class of protease inhibitors. They act by blocking the HIV protease enzyme, which is crucial for the cleavage of viral polyproteins into functional proteins. This inhibition prevents the virus from maturing and producing infectious particles, thereby controlling HIV proliferation in the patient’s body.

Darunavir serves as the primary antiviral agent, while Ritonavir functions as a pharmacokinetic enhancer, increasing Darunavir’s bioavailability and half-life in plasma, leading to improved therapeutic efficacy.


Dosage and Administration

  • Recommended Dose: One tablet (Darunavir 400mg + Ritonavir 50mg) to be taken orally twice daily with food.
  • Route of Administration: Oral
  • Duration of Treatment: As prescribed by the healthcare provider.

It is essential to take this medication consistently to maintain stable drug levels and ensure maximum suppression of the virus. Missing doses may lead to drug resistance or reduced effectiveness.

Common Side Effects

While Darunavir Ethanolate & Ritonavir Tablets are generally well-tolerated, some individuals may experience mild to moderate side effects such as:

  • Diarrhea
  • Nausea and vomiting
  • Abdominal pain
  • Headache
  • Dizziness
  • Increased cholesterol and triglyceride levels
  • Skin rash

Patients are advised to report any persistent or severe adverse effects to their healthcare provider immediately.


Why Choose Taj Pharma for Darunavir Ethanolate & Ritonavir Tablets 400mg/50mg Manufacturing?

Taj Pharma India has earned global recognition for its commitment to quality, innovation, and ethical manufacturing practices. Here’s why global buyers prefer Taj Pharma for their pharmaceutical sourcing needs:

1. World-Class Manufacturing Infrastructure

Taj Pharma operates state-of-the-art production facilities in Vapi, Gujarat, equipped with modern equipment and automated quality control systems. Every batch of Darunavir Ethanolate & Ritonavir Tablets undergoes rigorous testing for purity, potency, and uniformity.

2. Strong Export Network

Taj Pharma exports its products to over 40+ countries, including Africa, Latin America, Southeast Asia, and the Middle East. The company holds approvals from several national regulatory agencies, making it a trusted partner for global procurement agencies, NGOs, and health ministries.

3. Complete Regulatory Support

Taj Pharma provides complete regulatory documentation support including COA, COPP, Stability Data, and Dossier in CTD/eCTD formats, facilitating faster product registration in importing countries.

4. Competitive Pricing with Quality Assurance

By maintaining cost-efficient production processes, Taj Pharma ensures affordable pricing without compromising product quality—making it a preferred partner for public health tenders and humanitarian organizations.

5. Custom Manufacturing & Private Labeling

Taj Pharma offers customized formulation development, contract manufacturing, and private labeling services for distributors and pharmaceutical brands worldwide.


Global Presence – Reaching Every Market

Taj Pharma has established itself as a leading global supplier of Darunavir Ethanolate & Ritonavir Tablets 400mg/50mg, exporting to:

  • African Regions: Nigeria, Kenya, Tanzania, Ghana, South Africa
  • Middle East: UAE, Saudi Arabia, Oman, Kuwait, Yemen
  • LATAM: Peru, Bolivia, Colombia, Venezuela
  • Asia-Pacific: Myanmar, Sri Lanka, Cambodia, Philippines

Its reliable supply chain, compliance with local health authority regulations, and ability to deliver in bulk quantities make Taj Pharma the preferred choice for international buyers, hospitals, and healthcare agencies.


PCD Pharma Franchise and Third-Party Manufacturing Opportunities

Taj Pharma offers lucrative PCD Pharma Franchise and third-party manufacturing opportunities for partners interested in marketing Darunavir Ethanolate & Ritonavir Tablets 400mg/50mg across India and overseas markets.

Benefits include:

  • Monopoly-based marketing rights
  • Attractive packaging and promotional support
  • Exclusive distribution territory
  • Competitive pricing and high profit margins

Quality Certifications and Regulatory Approvals

Taj Pharma’s manufacturing facilities hold multiple international certifications including:

  • WHO-GMP Certification
  • ISO 9001:2015
  • GLP and cGMP Compliance
  • Approved by National and International Regulatory Bodies

Every product batch undergoes stringent testing through HPLC, UV spectroscopy, and stability chambers, ensuring the highest safety and quality standards.


The Benchmark in HIV Drug Manufacturing

As the 1 Darunavir Ethanolate & Ritonavir Tablets 400mg/50mg manufacturer, supplier, and exporter in India, Taj Pharma continues to drive global access to life-saving HIV teatments through affordable, high-quality medicines. Its dedication to innovation, integrity, and international compliance makes it the most dependable pharmaceutical partner for global buyers.

Whether you are a government procurement agency, distributor, or health organization, Taj Pharma ensures consistent supply, regulatory support, and unmatched product quality for all your antiretroviral drug requirements.